Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00764790 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,317
- Enrollment target
NCT00764790 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,317 participants.
The verdict
NCT00764790, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,317 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.
Interventions
- BIOLOGICAL Fluzone
- BIOLOGICAL Fluarix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,317 participants |
| Start Date | 2008-10-01 |
| Est. Completion | 2009-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00764790
The ClinicalTrials.gov registry entry for NCT00764790 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone is the first listed.
NCT00764790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00764790 about?
NCT00764790 is a clinical study titled "Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children". The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline Biologicals' seasonal influenza vaccine, Fluarix, compared to Fluzone (a US-licensed vaccine) in children, 6 to 35 months of age.
What is the current status of trial NCT00764790?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,317 participants. The study started on 2008-10-01. Estimated completion is 2009-06-01.
What interventions are being tested in trial NCT00764790?
The interventions under investigation include: Fluzone (BIOLOGICAL), Fluarix (BIOLOGICAL).
Who is sponsoring clinical trial NCT00764790?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.